ES3013859T3 - Mdm2 inhibitor, preparation method therefor, pharmaceutical composition thereof, and use thereof - Google Patents
Mdm2 inhibitor, preparation method therefor, pharmaceutical composition thereof, and use thereof Download PDFInfo
- Publication number
- ES3013859T3 ES3013859T3 ES19864128T ES19864128T ES3013859T3 ES 3013859 T3 ES3013859 T3 ES 3013859T3 ES 19864128 T ES19864128 T ES 19864128T ES 19864128 T ES19864128 T ES 19864128T ES 3013859 T3 ES3013859 T3 ES 3013859T3
- Authority
- ES
- Spain
- Prior art keywords
- substituted
- unsubstituted
- compound
- group
- chlorophenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811160163.0A CN110963958B (zh) | 2018-09-30 | 2018-09-30 | 一种mdm2抑制剂，及其制备方法、药物组合物和应用 |
| PCT/CN2019/109428 WO2020064004A1 (zh) | 2018-09-30 | 2019-09-30 | 一种mdm2抑制剂，及其制备方法、药物组合物和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3013859T3 true ES3013859T3 (en) | 2025-04-15 |
Family
ID=69949744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES19864128T Active ES3013859T3 (en) | 2018-09-30 | 2019-09-30 | Mdm2 inhibitor, preparation method therefor, pharmaceutical composition thereof, and use thereof |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11299460B2 (https=) |
| EP (1) | EP3858812B1 (https=) |
| JP (1) | JP7338896B2 (https=) |
| KR (1) | KR102610545B1 (https=) |
| CN (2) | CN110963958B (https=) |
| AU (1) | AU2019351530B2 (https=) |
| ES (1) | ES3013859T3 (https=) |
| WO (1) | WO2020064004A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114853731B (zh) * | 2021-02-04 | 2026-02-06 | 上海长森药业有限公司 | 一种双功能mdm2蛋白降解剂，及其制备方法、药物组合物和应用 |
| WO2023089375A1 (en) * | 2021-11-22 | 2023-05-25 | Ligature Therapeutics Pte, Ltd. | Therapeutic compounds and methods of use thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2998B1 (ar) * | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| US9376425B2 (en) * | 2011-09-27 | 2016-06-28 | Amgen, Inc. | Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer |
| WO2014134201A1 (en) * | 2013-02-28 | 2014-09-04 | Amgen Inc. | A benzoic acid derivative mdm2 inhibitor for the treatment of cancer |
| CN105358530A (zh) * | 2013-06-10 | 2016-02-24 | 美国安进公司 | 制备mdm2抑制剂的方法及其结晶形式 |
| BR112016010564A2 (pt) * | 2013-11-11 | 2017-10-10 | Amgen Inc | terapia de combinação incluindo um inibidor de mdm2 e um ou mais agentes farmaceuticamente ativos para tratamento de cânceres |
| US10759808B2 (en) * | 2016-04-06 | 2020-09-01 | The Regents Of The University Of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
| SG11201808728QA (en) * | 2016-04-06 | 2018-11-29 | Univ Michigan Regents | Mdm2 protein degraders |
| WO2018092020A1 (en) * | 2016-11-15 | 2018-05-24 | Novartis Ag | Dose and regimen for hdm2-p53 interaction inhibitors |
-
2018
- 2018-09-30 CN CN201811160163.0A patent/CN110963958B/zh active Active
-
2019
- 2019-09-30 KR KR1020217013158A patent/KR102610545B1/ko active Active
- 2019-09-30 EP EP19864128.4A patent/EP3858812B1/en active Active
- 2019-09-30 JP JP2021517766A patent/JP7338896B2/ja active Active
- 2019-09-30 ES ES19864128T patent/ES3013859T3/es active Active
- 2019-09-30 CN CN201980064565.7A patent/CN112867708B/zh active Active
- 2019-09-30 WO PCT/CN2019/109428 patent/WO2020064004A1/zh not_active Ceased
- 2019-09-30 AU AU2019351530A patent/AU2019351530B2/en active Active
- 2019-09-30 US US17/281,368 patent/US11299460B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019351530A1 (en) | 2021-05-27 |
| EP3858812A1 (en) | 2021-08-04 |
| US11299460B2 (en) | 2022-04-12 |
| AU2019351530B2 (en) | 2022-11-17 |
| WO2020064004A1 (zh) | 2020-04-02 |
| EP3858812A4 (en) | 2022-07-06 |
| EP3858812C0 (en) | 2024-12-18 |
| CN110963958B (zh) | 2025-10-10 |
| US20220002248A1 (en) | 2022-01-06 |
| JP2022502448A (ja) | 2022-01-11 |
| CN112867708B (zh) | 2023-05-12 |
| CN112867708A (zh) | 2021-05-28 |
| KR102610545B1 (ko) | 2023-12-05 |
| JP7338896B2 (ja) | 2023-09-05 |
| EP3858812B1 (en) | 2024-12-18 |
| KR20210093870A (ko) | 2021-07-28 |
| CN110963958A (zh) | 2020-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022120096A (ja) | サイクリン依存性キナーゼ阻害剤としての２－アミノ－ピリジンまたは２－アミノ－ピリミジン誘導体 | |
| CN110770242B (zh) | 作为vanin抑制剂的杂芳族化合物 | |
| JP2019509274A (ja) | 新規化合物 | |
| JP7187449B2 (ja) | Ｅｈｍｔ２阻害剤としての置換された融合二環式または三環式複素環化合物 | |
| WO2020103884A1 (en) | Cyclic Ureas | |
| AU2016382372B2 (en) | Sulfonamide derivative and preparation method and use thereof | |
| AU2020405536B2 (en) | Benzimidazole derivatives | |
| WO2016192630A1 (zh) | 一类具有激酶抑制活性的化合物、制备方法和用途 | |
| ES3013859T3 (en) | Mdm2 inhibitor, preparation method therefor, pharmaceutical composition thereof, and use thereof | |
| JP7667742B2 (ja) | Ａｔｐ競合性ａｋｔ阻害剤ｇｄｃ－００６８とｅ３リガーゼリガンドとの結合によるａｋｔの分解および使用方法 | |
| CA3206871A1 (en) | Pyrimidine compound as wee-1 inhibitor | |
| CN114853731B (zh) | 一种双功能mdm2蛋白降解剂，及其制备方法、药物组合物和应用 | |
| KR20250164146A (ko) | 치환된 설탐 화합물 유도체 및 이의 약제학적 용도 | |
| WO2024054602A1 (en) | Heterobifunctional compounds and methods of treating disease | |
| HK40043315B (en) | Mdm2 inhibitor, preparation method therefor, pharmaceutical composition thereof, and use thereof | |
| HK40043315A (en) | Mdm2 inhibitor, preparation method therefor, pharmaceutical composition thereof, and use thereof | |
| TW202537962A (zh) | 抑制α-V β-1整合素 | |
| TW202430501A (zh) | 醯基磺胺化合物作為多瘤病毒的抑制劑 | |
| OA20759A (en) | Benzimidazole derivatives. |